Clinical Trial Update: Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating deferiprone for the prevention of contrast-induced acute kidney injury has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Acute Kidney Injury

Drugs mentioned

• Deferiprone (deferiprone)

Snippet

Sponsor: CorMedix | Conditions: Contrast-Induced Acute Kidney Injury | Phase 2 | Status: COMPLETED